APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Metachromatic Leukodystrophy (MLD) Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Metachromatic Leukodystrophy (MLD) Treatment Industry Growth and Trends Forecast to 2032

Report ID 174012480122 December 202590 pages

Choose your research edition.

Industry ResearchMetachromatic Leukodystrophy (MLD) Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Metachromatic Leukodystrophy (MLD) Treatment Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Metachromatic Leukodystrophy (MLD) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metachromatic Leukodystrophy (MLD) Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metachromatic Leukodystrophy (MLD) Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Metachromatic Leukodystrophy (MLD) Treatment include Takeda, GlaxoSmithKline Plc, RegenxBio Inc, Recursion Pharmaceuticals Inc and ArmaGen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Metachromatic Leukodystrophy (MLD) Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Metachromatic Leukodystrophy (MLD) Treatment market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Metachromatic Leukodystrophy (MLD) Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Metachromatic Leukodystrophy (MLD) Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Metachromatic Leukodystrophy (MLD) Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Metachromatic Leukodystrophy (MLD) Treatment Market by Company

Takeda

GlaxoSmithKline Plc

RegenxBio Inc

Recursion Pharmaceuticals Inc

ArmaGen Inc

Metachromatic Leukodystrophy (MLD) Treatment Segment by Type

AGT-183

DUOC-01

GSK-2696274

Others

Metachromatic Leukodystrophy (MLD) Treatment Segment by Application

Hospital

Clinic

Others

Metachromatic Leukodystrophy (MLD) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metachromatic Leukodystrophy (MLD) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metachromatic Leukodystrophy (MLD) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metachromatic Leukodystrophy (MLD) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Metachromatic Leukodystrophy (MLD) Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Metachromatic Leukodystrophy (MLD) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of AGT-183 Table 2. Major Company of DUOC-01 Table 3. Major Company of GSK-2696274 Table 4. Major Company of Others Table 5. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 7. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type (2021-2026) Table 8. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (US$ Million) Table 9. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type (2021-2026) Table 10. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2026) & (US$/unit) Table 11. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 12. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type (2027-2032) Table 13. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (US$ Million) Table 14. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type (2027-2032) Table 15. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2027-2032) & (US$/unit) Table 16. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 17. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 19. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 23. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (US$ Million) Table 26. Metachromatic Leukodystrophy (MLD) Treatment Industry Trends Table 27. Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers Table 28. Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges Table 29. Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints Table 30. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Company (2021-2026) Table 32. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Company (2021-2026) & (k units) Table 33. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Company (2021-2026) Table 34. Global Metachromatic Leukodystrophy (MLD) Treatment Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Metachromatic Leukodystrophy (MLD) Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Metachromatic Leukodystrophy (MLD) Treatment Major Company Production Sites and Headquarters Table 37. Global Metachromatic Leukodystrophy (MLD) Treatment Company, Product Type & Application Table 38. Global Metachromatic Leukodystrophy (MLD) Treatment Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Metachromatic Leukodystrophy (MLD) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026) & (k units) Table 43. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Region (2021-2026) Table 44. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026) & (US$ Million) Table 45. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Region (2021-2026) Table 46. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2027-2032) & (k units) Table 48. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Region (2027-2032) Table 49. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2027-2032) & (US$ Million) Table 50. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Region (2027-2032) Table 51. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 54. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application (2021-2026) Table 55. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (US$ Million) Table 56. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application (2021-2026) Table 57. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2026) & (US$/unit) Table 58. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 59. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application (2027-2032) Table 60. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (US$ Million) Table 61. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application (2027-2032) Table 62. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2027-2032) & (US$/unit) Table 63. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 64. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 66. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 70. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Company Information Table 74. Takeda Business Overview Table 75. Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 77. Takeda Recent Development Table 78. GlaxoSmithKline Plc Company Information Table 79. GlaxoSmithKline Plc Business Overview Table 80. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 82. GlaxoSmithKline Plc Recent Development Table 83. RegenxBio Inc Company Information Table 84. RegenxBio Inc Business Overview Table 85. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 87. RegenxBio Inc Recent Development Table 88. Recursion Pharmaceuticals Inc Company Information Table 89. Recursion Pharmaceuticals Inc Business Overview Table 90. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 92. Recursion Pharmaceuticals Inc Recent Development Table 93. ArmaGen Inc Company Information Table 94. ArmaGen Inc Business Overview Table 95. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 97. ArmaGen Inc Recent Development Table 98. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 99. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 100. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2021-2026) Table 101. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032) & (k units) Table 102. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share Forecast by Country (2027-2032) Table 103. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 105. North America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country (2021-2026) Table 106. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. North America Metachromatic Leukodystrophy (MLD) Treatment Market Share Forecast by Country (2027-2032) Table 108. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 109. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 110. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2021-2026) Table 111. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032) & (k units) Table 112. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share Forecast by Country (2027-2032) Table 113. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country (2021-2026) Table 116. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 120. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2021-2026) Table 121. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032) & (k units) Table 122. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 125. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country (2021-2026) Table 126. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Share Forecast by Country (2027-2032) Table 128. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 129. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 130. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2021-2026) Table 131. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032) & (k units) Table 132. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share Forecast by Country (2027-2032) Table 133. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country (2021-2026) Table 136. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 140. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2021-2026) Table 141. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032) & (k units) Table 142. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share Forecast by Country (2027-2032) Table 143. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country (2021-2026) Table 146. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Share Forecast by Country (2027-2032) Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Metachromatic Leukodystrophy (MLD) Treatment Distributors List Table 151. Metachromatic Leukodystrophy (MLD) Treatment Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Metachromatic Leukodystrophy (MLD) Treatment Image Figure 2. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (2021-2032) & (k units) Figure 5. AGT-183 Image Figure 6. Global AGT-183 Sales YoY Growth (2021-2032) & (k units) Figure 7. DUOC-01 Image Figure 8. Global DUOC-01 Sales YoY Growth (2021-2032) & (k units) Figure 9. GSK-2696274 Image Figure 10. Global GSK-2696274 Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type 2025 VS 2032 Figure 15. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type in 2025 Figure 16. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type in 2025 Figure 17. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type in 2025 Figure 18. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type in 2025 Figure 21. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Metachromatic Leukodystrophy (MLD) Treatment Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application 2025 VS 2032 Figure 35. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application in 2025 Figure 36. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application in 2025 Figure 37. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application in 2025 Figure 38. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application in 2025 Figure 41. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share in Value by Application in 2025 Figure 45. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Metachromatic Leukodystrophy (MLD) Treatment Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • AGT-183
  • DUOC-01
  • GSK-2696274
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda
  • GlaxoSmithKline Plc
  • RegenxBio Inc
  • Recursion Pharmaceuticals Inc
  • ArmaGen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Metachromatic Leukodystrophy (MLD) Treatment Market by Type
  6. 1.3.1 AGT-183
  7. 1.3.2 DUOC-01
  8. 1.3.3 GSK-2696274
  9. 1.3.4 Others
  10. 1.4 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
  11. 1.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
  2. 2.2 Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers
  3. 2.3 Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges
  4. 2.4 Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2026)
  2. 3.2 Global Top Players by Metachromatic Leukodystrophy (MLD) Treatment Sales (2021-2026)
  3. 3.3 Global Top Players by Metachromatic Leukodystrophy (MLD) Treatment Price (2021-2026)
  4. 3.4 Global Metachromatic Leukodystrophy (MLD) Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Metachromatic Leukodystrophy (MLD) Treatment Major Company Production Sites & Headquarters
  6. 3.6 Global Metachromatic Leukodystrophy (MLD) Treatment Company, Product Type & Application
  7. 3.7 Global Metachromatic Leukodystrophy (MLD) Treatment Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Metachromatic Leukodystrophy (MLD) Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Metachromatic Leukodystrophy (MLD) Treatment Tier 1, Tier 2, and Tier 3
4 Metachromatic Leukodystrophy (MLD) Treatment Regional Status and Outlook
  1. 4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Historic Market Size by Region
  3. 4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Market Size by Region
  7. 4.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Metachromatic Leukodystrophy (MLD) Treatment by Application
  1. 5.1 Metachromatic Leukodystrophy (MLD) Treatment Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
  6. 5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 GlaxoSmithKline Plc
  8. 6.2.1 GlaxoSmithKline Plc Company Information
  9. 6.2.2 GlaxoSmithKline Plc Business Overview
  10. 6.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  12. 6.2.5 GlaxoSmithKline Plc Recent Developments
  13. 6.3 RegenxBio Inc
  14. 6.3.1 RegenxBio Inc Company Information
  15. 6.3.2 RegenxBio Inc Business Overview
  16. 6.3.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  18. 6.3.5 RegenxBio Inc Recent Developments
  19. 6.4 Recursion Pharmaceuticals Inc
  20. 6.4.1 Recursion Pharmaceuticals Inc Company Information
  21. 6.4.2 Recursion Pharmaceuticals Inc Business Overview
  22. 6.4.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  24. 6.4.5 Recursion Pharmaceuticals Inc Recent Developments
  25. 6.5 ArmaGen Inc
  26. 6.5.1 ArmaGen Inc Company Information
  27. 6.5.2 ArmaGen Inc Business Overview
  28. 6.5.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  30. 6.5.5 ArmaGen Inc Recent Developments
7 North America by Country
  1. 7.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
  2. 7.1.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026)
  4. 7.1.3 North America Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032)
  5. 7.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  6. 7.2.1 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026)
  8. 7.2.3 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
  2. 8.1.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026)
  4. 8.1.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  6. 8.2.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026)
  8. 8.2.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
  2. 9.1.1 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  6. 9.2.1 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
  2. 10.1.1 South America Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026)
  4. 10.1.3 South America Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032)
  5. 10.2 South America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  6. 10.2.1 South America Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026)
  8. 10.2.3 South America Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country
  2. 11.1.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  6. 11.2.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Metachromatic Leukodystrophy (MLD) Treatment Value Chain Analysis
  2. 12.1.1 Metachromatic Leukodystrophy (MLD) Treatment Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process
  7. 12.2 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
  10. 12.2.3 Metachromatic Leukodystrophy (MLD) Treatment Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst